Catherine Bollard, MD, MBChB

Bio

Biography

Dr. Catherine Bollard is the director of the Center for Cancer and Immunology Research at the Children’s Research Institute, a member of the Division of the Blood and Marrow Transplantation, and the Principal Investigator and Co-Director of the Immunology Initiative of the Sheikh Zayed Institute for Pediatric Surgical Innovation. In this role, she leads clinical and research efforts to fight cancer and other inflammatory diseases by strengthening a child’s immune system. As the current President of the International Society of Cellular Therapy, she is a distinguished hematologist and immunotherapist, working to develop cell and gene therapies for patients with cancer and underlying immune deficiencies.

Additionally, Dr. Bollard is interested in stem cell and cord blood transplantation, and improving outcomes by decreasing infectious complications and preventing relapse. She also has a specific interest in targeting viral infections in the immune suppression population, including individuals living with HIV. Further, building on her focus developing cell therapies for EBV-associated lymphomas and as head of the NHL committee of the Children’s Oncology Group, she has moved T-cell therapies to the cooperative group setting.

As a national and international leader in the immunology and immunotherapy space, Dr. Bollard’s work expands our understanding of cancer in pediatric patients. She joined Children’s National from the Baylor College of Medicine where she was a tenured Professor in the Department of Pediatrics. Prior to that, she served as a Postdoctoral Fellow at Texas Children’s Hospital. Dr. Bollard received her medical degree from Otago University Medical School in New Zealand.

Education & Training

Education & Training

  • MD, 2005
    University of Otago
  • Fellowship Program, Peds Bone Marrow Transplant, 2001
    Texas Children's Hospital
  • Fellowship Program, Pediatric Hematology/Oncology, 2000
    Auckland University Hospital
  • Residency Program, Pediatric Hematology/Oncology, 1994
    Saint Bartholomew's Hospital
  • Residency Program, General Medicine, 1993
    Auckland University Hospital
  • MBCHB, 1991
    University of Otago
News

News

Children’s National becomes first pediatric medical institution in the United States to receive combined FACT accreditation related to cellular immunotherapy

Today Children’s National Health System became the first pediatric medical institution in the United States to receive accreditations for both immune effector cells and more than minimal manipulation from the Foundation for the Accreditation of Cellular Therapy (FACT). Considered the threshold for excellence in cellular therapy, FACT establishes standards for high-quality medical and laboratory practice in the field.   

Invest in future cures for some of life's most devastating diseases

See other ways to give

Share your birthday with a child. Celebrate your life, and give a chance to someone who desperately wants to have as many as you.

Share your birthday with a child. Celebrate your life, and give a chance to someone who desperately wants to have as many as you. Make it happen

Christopher's Story

christopher teaser image

Christopher Melkonian was six years old when he came down with a low-grade fever and diffuse bone pain. Unsure of what was happening, his parents Darlene and David took him to Children’s National Health System and soon found out that Christopher had acute lymphoblastic leukemia (ALL), a type of blood and bone marrow cancer that affects white blood cells.

Read More of Christopher's Story